Please assess the completion status of the following clinical trial:

Trial Title: A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~For CML patients either:~* a. Patients with Ph+ CML in chronic or accelerated phase who were previously treated with at least two different tyrosine kinase inhibitors prior to study entry and are relapsed, refractory to or intolerant of TKIs as determined by investigators or~* b. Patients with CML in chronic or accelerated phase who exhibit relapsed disease associated with the presence of the T315I gatekeeper mutation after at least one TKI are also eligible provided that no other effective therapy exists~For ALL and CML-BP patients:~* Patients with CML BP or Ph+ ALL who have a cytopathologically confirmed diagnosis and are relapsed or refractory to at least one prior TKI or intolerant of TKIs. TKI failure for Ph+ ALL and CML-BP patients is defined as at least the loss of Molecular Response (MR) 4.5 (BCR-ABL ≤ 0.0032%)~* Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2~* Willingness and ability to comply with all study procedures~* Written informed consent obtained prior to any screening procedures~Exclusion Criteria:~Wash-out period:~* Systemic antineoplastic therapy (including cytotoxic chemotherapy, alfa-interferon and toxin immunoconjugates) or any experimental therapy within 14 days or 5 half-lives, whichever is shorter, before the first dose of study treatment~* Therapy with TKIs as single agent within 5 half-lives before the first dose of study treatment~* Unconjugated monoclonal antibody therapies within 28 days or 5 half-lives, whichever is shorter, before the first dose of study treatment~* For patients receiving ABL001 in combination with either nilotinib or imatinib or dasatinib, intolerance to nilotinib, imatinib or dasatinib, respectively~* Radiotherapy with a wide field of radiation within 4 weeks or radiotherapy with a limited field of radiation for palliation within 1 week of the first dose of study treatment.~* CNS irradiation for meningeal leukemia, except if radiotherapy occurred \> 3 months previously. At least four weeks must have elapsed since prophylactic CNS irradiation given as part of a front-line therapy regimen for ALL~* Major surgery within 2 weeks before the first dose of study treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Asciminib in CML patients (Type: EXPERIMENTAL): Dose escalation study estimated the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) of asciminib in adult patients with chronic myeloid leukemia (CML).
- Asciminib+Nilotinib in CML patients (Type: EXPERIMENTAL): Dose escalation study estimated the MTD and/or RDE of asciminib in combination with Nilotinib in adult CML patients
- Asciminib in Ph+ ALL patients (Type: EXPERIMENTAL): Dose escalation study estimated the MTD and/or RDE of asciminib in adult patients with Ph positive ALL patients
- Asciminib+Imatinib in CML patients (Type: EXPERIMENTAL): Dose escalation study to estimate the MTD and/or RDE of asciminib in combination with imatinib in adult CML patients
- Asciminib+dasatinib in CML patients (Type: EXPERIMENTAL): Dose escalation study estimated the MTD and/or RDE of asciminib in combination with dasatinib in adult CML patients

Based on this trial design, predict the completion outcome and termination type (if applicable).